Swiss drug major Roche Holding AG (RHHBY) announced Wednesday that the phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer or ES-SCLC did not meet its co-primary endpoint of progression-free survival.
The trial evaluated the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as an initial or first-line treatment for people with ES-SCLC.
For comments and feedback contact: editorial@rttnews.com
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.